A detailed history of Avoro Capital Advisors LLC transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Avoro Capital Advisors LLC holds 4,500,000 shares of KYMR stock, worth $183 Million. This represents 3.21% of its overall portfolio holdings.

Number of Shares
4,500,000
Previous 3,888,888 15.71%
Holding current value
$183 Million
Previous $116 Million 83.48%
% of portfolio
3.21%
Previous 1.58%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$30.16 - $52.4 $18.4 Million - $32 Million
611,112 Added 15.71%
4,500,000 $213 Million
Q1 2024

May 15, 2024

BUY
$22.9 - $43.57 $2.61 Million - $4.96 Million
113,888 Added 3.02%
3,888,888 $156 Million
Q4 2023

Feb 14, 2024

SELL
$10.97 - $26.84 $877,600 - $2.15 Million
-80,000 Reduced 2.08%
3,775,000 $96.1 Million
Q1 2023

May 15, 2023

BUY
$24.84 - $38.75 $124,200 - $193,750
5,000 Added 0.13%
3,855,000 $114 Million
Q4 2022

Feb 14, 2023

BUY
$19.57 - $30.92 $32.9 Million - $52 Million
1,680,770 Added 77.48%
3,850,000 $96.1 Million
Q3 2022

Nov 14, 2022

BUY
$20.91 - $34.27 $19 Million - $31.2 Million
909,230 Added 72.16%
2,169,230 $47.2 Million
Q2 2022

Aug 15, 2022

BUY
$14.13 - $42.55 $6.27 Million - $18.9 Million
443,500 Added 54.32%
1,260,000 $24.8 Million
Q1 2022

May 16, 2022

BUY
$35.3 - $64.68 $9.41 Million - $17.2 Million
266,500 Added 48.45%
816,500 $34.6 Million
Q4 2021

Feb 14, 2022

BUY
$49.91 - $65.56 $4.7 Million - $6.18 Million
94,250 Added 20.68%
550,000 $34.9 Million
Q3 2021

Nov 15, 2021

BUY
$47.8 - $66.66 $21.8 Million - $30.4 Million
455,750 New
455,750 $26.8 Million
Q4 2020

Feb 16, 2021

SELL
$28.07 - $87.83 $1.39 Million - $4.34 Million
-49,400 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$26.1 - $33.28 $1.29 Million - $1.64 Million
49,400 New
49,400 $1.6 Million

Others Institutions Holding KYMR

About Kymera Therapeutics, Inc.


  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $2.22B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track This Portfolio

Track Avoro Capital Advisors LLC Portfolio

Follow Avoro Capital Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avoro Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Avoro Capital Advisors LLC with notifications on news.